 VANCOUVER, Washington, Sept. 19, 2022 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY CytoDyn or the Company, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Kelly, Chief Medical Officer and Head of Business Development, will host an investment community webcast to provide a quarterly Company update on Wednesday, September 28, 2022. 